FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Pete O'Heeron, will deliver a presentation on September 10 at 12:00 p.m. ET at the Lotte New York Palace Hotel. The company, which holds over 275 patents issued and pending, will also be available for one-on-one meetings with investors during the conference.
FibroBiologics (Nasdaq: FBLG), società biotecnologica in fase clinica che sviluppa terapie basate su fibroblasti e materiali derivati da fibroblasti, prenderà parte al 27° H.C. Wainwright Annual Global Investment Conference.
Il CEO Pete O'Heeron terrà una presentazione il 10 settembre alle 12:00 ET presso il Lotte New York Palace Hotel. L'azienda, titolare di oltre 275 brevetti concessi e in attesa, sarà inoltre disponibile per incontri individuali con gli investitori durante la conferenza.
FibroBiologics (Nasdaq: FBLG), una biotecnológica en fase clínica centrada en el desarrollo de terapias con fibroblastos y materiales derivados de fibroblastos, participará en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright.
El director ejecutivo, Pete O'Heeron, ofrecerá una presentación el 10 de septiembre a las 12:00 p.m. ET en el Lotte New York Palace Hotel. La compañía, que cuenta con más de 275 patentes concedidas y en trámite, también estará disponible para reuniones individuales con inversores durante la conferencia.
FibroBiologics (Nasdaq: FBLG)는 섬유아세포 및 섬유아세포 유래 소재를 활용한 치료제 개발에 주력하는 임상 단계의 바이오테크 기업으로, H.C. Wainwright 27회 연례 글로벌 투자 콘퍼런스에 참가합니다.
최고경영자(CEO) 피트 오히런(Pete O'Heeron)은 현지시간 9월 10일 오후 12시(ET) Lotte New York Palace Hotel에서 발표를 진행합니다. 발행 및 출원 중인 275건 이상의 특허를 보유한 이 회사는 컨퍼런스 기간 동안 투자자들과의 일대일 미팅도 예정하고 있습니다.
FibroBiologics (Nasdaq: FBLG), une société de biotechnologie en phase clinique spécialisée dans le développement de traitements utilisant des fibroblastes et des matériaux dérivés de fibroblastes, participera à la 27e Conférence annuelle mondiale d'investissement H.C. Wainwright.
Le directeur général, Pete O'Heeron, fera une présentation le 10 septembre à 12h00 ET au Lotte New York Palace Hotel. L'entreprise, qui détient plus de 275 brevets délivrés et en cours, sera également disponible pour des réunions individuelles avec des investisseurs pendant la conférence.
FibroBiologics (Nasdaq: FBLG), ein biotechnologisches Unternehmen in der klinischen Phase, das Therapeutika auf Basis von Fibroblasten und fibroblastabgeleiteten Materialien entwickelt, wird an der 27. H.C. Wainwright Annual Global Investment Conference teilnehmen.
Der CEO Pete O'Heeron wird am 10. September um 12:00 Uhr ET im Lotte New York Palace Hotel eine Präsentation halten. Das Unternehmen, das über mehr als 275 erteilte und anhängige Patente verfügt, steht während der Konferenz außerdem für Einzelgespräche mit Investoren zur Verfügung.
- None.
- None.
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10 at the Lotte New York Palace Hotel in New York City.
FibroBiologics will deliver a company presentation at 12:00 p.m. ET on September 10 and be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) presenting at the H.C. Wainwright Conference?
Who will be presenting for FibroBiologics at the H.C. Wainwright Conference?
How many patents does FibroBiologics (FBLG) have?
What is FibroBiologics' (FBLG) main focus as a company?
Where can investors get more information about FibroBiologics' presentation?
